- Investing.com
Rytelo's Promise | Explore Geron's market position as Rytelo's launch metrics show early success, potentially reshaping the biopharmaceutical landscape |
Financial Trajectory | Delve into Geron's financial performance, with FY2024 EPS at -$0.38 and FY2025 at -$0.20, reflecting typical biotech growth patterns |
Strategic IP Moat | Discover how Geron's MoU patents could extend product exclusivity beyond 2035, potentially securing long-term market dominance |
Analyst Optimism | Barclays maintains an Overweight rating with a $9.00 price target, signaling confidence in Geron's growth potential and market positioning |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Metrics to compare | GERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGERNPeersSector | |
---|---|---|---|---|
P/E Ratio | −11.9x | −3.0x | −0.6x | |
PEG Ratio | - | −0.04 | 0.00 | |
Price/Book | 8.5x | 3.1x | 2.6x | |
Price / LTM Sales | 1,901.0x | 8.7x | 3.2x | |
Upside (Analyst Target) | 61.7% | 308.6% | 43.9% | |
Fair Value Upside | Unlock | 21.5% | 7.8% | Unlock |